Prof. Schroeder’s focus is on the development of targeted and more personalized medicines, including nanotechnology. His research group aims to improve patients’ quality of life and treatment by developing innovative medical technologies. He and his team focus on targeted drug delivery systems to treat neurodegenerative diseases of the brain. They utilize their technology to treat metastatic cancers, and they combine their technology with synthetic biology to develop artificial cells for therapeutic applications.

Prof. Schroeder is the recipient of more than 30 national and international awards, including being named a KAVLI Fellow and recipient of the Intel Nanotechnology, TEVA Pharmaceuticals, and Wolf Foundation Krill Awards. He is the author of more than 70 papers, the inventor of over 20 patents, and co-founder of multiple startup companies based on these discoveries.

He is a former member of the Israel Young National Academy of Sciences, a current member of Israel’s National Council for Civilian Research and Development, and the President-elect of the Controlled Release Society (CRS). He conducted his postdoctoral studies at the Massachusetts Institute of Technology and completed his Ph.D. jointly at the Hebrew University of Jerusalem and Ben-Gurion University of the Negev.